68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours-Reference-Cited by-同舟云学术

68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours

Published:2019-12 Issue: Volume:141 Page:108-115
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Sharma Rohini,Wang Wai Meng,Yusuf Siraj,Evans Joanne,Ramaswami Ramya,Wernig Florian,Frilling Andrea,Mauri Francesco,Al-Nahhas Adil,Aboagye Eric O.,Barwick Tara D.

Funder

Imperial NIHR Biomedical Research Centre

Imperial Experimental Cancer Medicines Centre

Cancer Research UK

UK Medical Research Council

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference28 articles.

1. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017

2. Lutetium-labelled peptides for therapy of neuroendocrine tumours;Kam;Eur J Nucl Med Mol Imaging,2012

3. 177Lu-dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med.,2017

4. Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues;Muros;Clin Transl Oncol,2009

5. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas;Grozinsky-Glasberg;Cancer,2011

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies;Current Problems in Cancer;2024-10

2. Deep Learning-powered CT-less Multi-tracer Organ Segmentation from PET Images: A solution for unreliable CT segmentation in PET/CT Imaging;2024-08-28

3. Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT;EJNMMI Reports;2024-08-08

4. Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors;JCO Oncology Practice;2024-06-27

5. Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients;Radiology and Oncology;2024-06-12